Oral Brown Spots Not Predictive of Retinal Toxicity in Patients Taking Antimalarial Drugs for Lupus
Oral pigmented macules in the buccal mucosa of patients taking antimalarial therapy for systemic lupus erythematosus (SLE) do not predict retinal toxicity, according to a study published online in the journal Lupus.
“The prolonged use of chloroquine and hydroxychloroquine can cause hyperpigmentation in the skin, oral mucosa, and retinal pigment epithelium, which in turn can trigger toxicity in this epithelium, which in some cases causes vision loss,” researchers wrote. “The objective of the present work was to establish the association between the presence of oral pigmented macules by antimalarial and secondary retinal toxicity.
_________________________________________________________________
Related content....
Low Disease Activity Is Attainable Goal in New SLE Patients
Worsening MRI Associated With New Neuropsychiatric Events in SLE
_________________________________________________________________
The study included 105 patients with SLE treated with chloroquine and hydroxychloroquine. All participants received retinopathy screening, and patients with oral hyperpigmented maculae underwent an incisional biopsy.
Oral brown spots were infrequent, affecting just 9.5% of participants, according to the study.
“Histopathologically, 100% of the oral macules showed characteristics of oral pigmentation by drug,” researchers reported, “and 100% ophthalmological parameters of normality.”
Although two patients were diagnosed with pre-retinopathy, neither had oral lesions, the study found.
—Jolynn Tumolo
Reference
Chacón-Dulcey V, López-Labady J, Villarroel-Dorrego M, et al. Oral manifestations associated with antimalarial therapy in patients with systemic lupus erythematosus [published online ahead of print May 3, 2020]. Lupus. doi:10.1177/0961203320922620


